Literature DB >> 31804389

Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study.

Alessandra Pulvirenti1, Georgios A Margonis2, Vicente Morales-Oyarvide3, Caitlin A McIntyre1, Sharon A Lawrence1, Debra A Goldman4, Mithat Gonen4, Matthew J Weiss2, Cristina R Ferrone3, Jin He2, Murray F Brennan1, John L Cameron2, Keith D Lillemoe3, T Peter Kingham1, Vinod Balachandran1, Motaz Qadan3, Michael I D'Angelica1, William R Jarnagin1, Christopher L Wolfgang2, Carlos Fernández-Del Castillo3, Peter J Allen5.   

Abstract

OBJECTIVE: To evaluate the influence of consensus guidelines on the management of intraductal papillary mucinous neoplasms (IPMN) and the subsequent changes in pathologic outcomes.
BACKGROUND: Over time, multiple guidelines have been developed to identify high-risk IPMN. We hypothesized that the development and implementation of guidelines should have increased the percentage of resected IPMN with high-risk disease.
METHODS: Memorial Sloan-Kettering (MSK), Johns Hopkins (JH), and Massachusetts General Hospital (MGH) databases were queried for resected IPMN (2000-2015). Patients were categorized into main-duct (MD-IPMN) versus branch-duct (BD-IPMN). Guideline-specific radiographic/endoscopic features were recorded. High-risk disease was defined as high-grade dysplasia/carcinoma. Fisher's exact test was used to detect differences between institutions. Logistic regression evaluated differences between time-points [preguidelines (pre-GL, before 2006), Sendai (SCG, 2006-2012), Fukuoka (FCG, after 2012)].
RESULTS: The study included 1210 patients. The percentage of BD-IPMN with ≥1 high-risk radiographic feature differed between centers (MSK 69%, JH 60%, MGH 45%; P < 0.001). In MD-IPMN cohort, the presence of radiographic features such as solid component and main pancreatic duct diameter ≥10 mm also differed (solid component: MSK 38%, JH 30%, MGH 18%; P < 0.001; duct ≥10 mm: MSK 49%, JH 32%, MGH 44%; P < 0.001). The percentage of high-risk disease on pathology, however, was similar between institutions (BD-IPMN: P = 0.36, MD-IPMN: P = 0.48). During the study period, the percentage of BD-IPMN resected with ≥1 high-risk feature increased (52% pre-GL vs 67% FCG; P = 0.005), whereas the percentage of high-risk disease decreased (pre-GL vs FCG: 30% vs 20%). For MD-IPMN, there was not a clear trend towards guideline adherence, and the rate of high-risk disease was similar over the time (pre-GL vs FCG: 69% vs 67%; P = 0.63).
CONCLUSION: Surgical management of IPMN based on radiographic criteria is variable between institutions, with similar percentages of high-risk disease. Over the 15-year study period, the rate of BD-IPMN resected with high-risk radiographic features increased; however, the rate of high-risk disease decreased. Better predictors are needed.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 31804389      PMCID: PMC8503800          DOI: 10.1097/SLA.0000000000003703

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  28 in total

1.  Comparison of the international consensus guidelines for predicting malignancy in intraductal papillary mucinous neoplasms.

Authors:  Suguru Yamada; Tsutomu Fujii; Kenta Murotani; Mitsuro Kanda; Hiroyuki Sugimoto; Goro Nakayama; Masahiko Koike; Michitaka Fujiwara; Akimasa Nakao; Yasuhiro Kodera
Journal:  Surgery       Date:  2015-10-23       Impact factor: 3.982

2.  Are the Current Guidelines for the Surgical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas Adequate? A Multi-Institutional Study.

Authors:  Gregory C Wilson; Shishir K Maithel; David Bentrem; Daniel E Abbott; Sharon Weber; Clifford Cho; Robert C G Martin; Charles R Scoggins; Hong Jin Kim; Nipun B Merchant; David A Kooby; Michael J Edwards; Syed A Ahmad
Journal:  J Am Coll Surg       Date:  2017-01-11       Impact factor: 6.113

3.  American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts.

Authors:  Santhi Swaroop Vege; Barry Ziring; Rajeev Jain; Paul Moayyedi
Journal:  Gastroenterology       Date:  2015-04       Impact factor: 22.682

Review 4.  Evaluation of the Fukuoka Consensus Guidelines for intraductal papillary mucinous neoplasms of the pancreas: Results from a systematic review of 1,382 surgically resected patients.

Authors:  Brian K P Goh; Zhimin Lin; Damien M Y Tan; Choon-Hua Thng; Christopher J L Khor; Tony K H Lim; London L P J Ooi; Alexander Y F Chung
Journal:  Surgery       Date:  2015-05-29       Impact factor: 3.982

5.  Does preoperative cross-sectional imaging accurately predict main duct involvement in intraductal papillary mucinous neoplasm?

Authors:  M R Barron; A M Roch; J A Waters; J A Parikh; J M DeWitt; M A Al-Haddad; E P Ceppa; M G House; N J Zyromski; A Nakeeb; H A Pitt; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2014-01-09       Impact factor: 3.452

6.  A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients.

Authors:  Peter J Allen; Michael D'Angelica; Mithat Gonen; David P Jaques; Daniel G Coit; William R Jarnagin; Ronald DeMatteo; Yuman Fong; Leslie H Blumgart; Murray F Brennan
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

7.  Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period.

Authors:  Sébastien Gaujoux; Murray F Brennan; Mithat Gonen; Michael I D'Angelica; Ronald DeMatteo; Yuman Fong; Mark Schattner; Christopher DiMaio; Maria Janakos; William R Jarnagin; Peter J Allen
Journal:  J Am Coll Surg       Date:  2011-04       Impact factor: 6.113

8.  A combination of molecular markers and clinical features improve the classification of pancreatic cysts.

Authors:  Simeon Springer; Yuxuan Wang; Marco Dal Molin; David L Masica; Yuchen Jiao; Isaac Kinde; Amanda Blackford; Siva P Raman; Christopher L Wolfgang; Tyler Tomita; Noushin Niknafs; Christopher Douville; Janine Ptak; Lisa Dobbyn; Peter J Allen; David S Klimstra; Mark A Schattner; C Max Schmidt; Michele Yip-Schneider; Oscar W Cummings; Randall E Brand; Herbert J Zeh; Aatur D Singhi; Aldo Scarpa; Roberto Salvia; Giuseppe Malleo; Giuseppe Zamboni; Massimo Falconi; Jin-Young Jang; Sun-Whe Kim; Wooil Kwon; Seung-Mo Hong; Ki-Byung Song; Song Cheol Kim; Niall Swan; Jean Murphy; Justin Geoghegan; William Brugge; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Richard Schulick; Barish H Edil; Volkan Adsay; Jorge Paulino; Jeanin van Hooft; Shinichi Yachida; Satoshi Nara; Nobuyoshi Hiraoka; Kenji Yamao; Susuma Hijioka; Schalk van der Merwe; Michael Goggins; Marcia Irene Canto; Nita Ahuja; Kenzo Hirose; Martin Makary; Matthew J Weiss; John Cameron; Meredith Pittman; James R Eshleman; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Rachel Karchin; Ralph H Hruban; Bert Vogelstein; Anne Marie Lennon
Journal:  Gastroenterology       Date:  2015-08-04       Impact factor: 22.682

9.  Cystic lesions of the pancreas: selection criteria for operative and nonoperative management in 209 patients.

Authors:  Peter J Allen; David P Jaques; Michael D'Angelica; Wilbur B Bowne; Kevin C Conlon; Murray F Brennan
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.452

10.  Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients.

Authors:  Mario Pelaez-Luna; Suresh T Chari; Thomas C Smyrk; Naoki Takahashi; Jonathan E Clain; Michael J Levy; Randall K Pearson; Bret T Petersen; Mark D Topazian; Santhi S Vege; Michael Kendrick; Michael B Farnell
Journal:  Am J Gastroenterol       Date:  2007-08       Impact factor: 10.864

View more
  4 in total

1.  Multimodal radiomics and cyst fluid inflammatory markers model to predict preoperative risk in intraductal papillary mucinous neoplasms.

Authors:  Kate A Harrington; Travis L Williams; Sharon A Lawrence; Jayasree Chakraborty; Mohammad A Al Efishat; Marc A Attiyeh; Gokce Askan; Yuting Chou; Alessandra Pulvirenti; Caitlin A McIntyre; Mithat Gonen; Olca Basturk; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; William R Jarnagin; Jeffrey A Drebin; Richard K Do; Peter J Allen; Amber L Simpson
Journal:  J Med Imaging (Bellingham)       Date:  2020-06-25

2.  ASO Author Reflections: Poorest Survival Outcomes in Patients with Right Colon Cancer with KRAS Mutation After Simultaneous Curative-Intent Surgery for Colorectal Cancer Liver Metastases.

Authors:  Ho Seung Kim; Nam Kyu Kim
Journal:  Ann Surg Oncol       Date:  2020-08-19       Impact factor: 5.344

3.  Prognosis of Synchronous Colorectal Liver Metastases After Simultaneous Curative-Intent Surgery According to Primary Tumor Location and KRAS Mutational Status.

Authors:  Ho Seung Kim; Jong Min Lee; Han Sang Kim; Seung Yoon Yang; Yoon Dae Han; Min Soo Cho; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim
Journal:  Ann Surg Oncol       Date:  2020-08-18       Impact factor: 5.344

4.  Evidence-Based Guidelines for Branch-Duct Intraductal Papillary Mucinous Neoplasm Management: Still a Lot of Room to Grow.

Authors:  Patricia C Conroy; Eric Nakakura
Journal:  JAMA Surg       Date:  2021-07-01       Impact factor: 16.681

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.